American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease

Jonathan P Terdiman; Claudia B Gruss; Joel J Heidelbaugh; Shahnaz Sultan; Yngve T Falck-Ytter; AGA Institute Clinical Practice and Quality Management Committee

doi:10.1053/j.gastro.2013.10.047

American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease

Gastroenterology. 2013 Dec;145(6):1459-63. doi: 10.1053/j.gastro.2013.10.047.

Authors

Jonathan P Terdiman¹, Claudia B Gruss, Joel J Heidelbaugh, Shahnaz Sultan, Yngve T Falck-Ytter; AGA Institute Clinical Practice and Quality Management Committee

Collaborators

AGA Institute Clinical Practice and Quality Management Committee:
Spencer D Dorn, Sharon L Dudley-Brown, Joseph K Lim, Lena B Palmer, Yvonne Romero, Joel H Rubenstein, David S Weinberg, Yu-Xiao Yang

Affiliation

¹ Division of Gastroenterology, University of California, San Francisco School of Medicine, San Francisco, California.

PMID: 24267474
DOI: 10.1053/j.gastro.2013.10.047

No abstract available

Keywords: AGA; American Gastroenterological Association Institute; CD; Crohn's disease; Development and Evaluation; GRADE; Grading of Recommendations Assessment; PICO; TNF; and outcome; comparator; intervention; population; tumor necrosis factor.

Publication types

Practice Guideline

MeSH terms

Azathioprine / therapeutic use*
Crohn Disease / drug therapy*
Gastroenterology
Humans
Mercaptopurine / therapeutic use*
Methotrexate / therapeutic use*
Remission Induction
Societies, Medical
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
United States

Substances

Tumor Necrosis Factor-alpha
Mercaptopurine
Azathioprine
Methotrexate